Entecavir Monohydrate
- ETV; Baraclude; SQ 34676; BMS 200475; SQ34676; BMS200475; SQ-34676; BMS-200475
货号： abs811046
| 货号-规格 | 货期 | 价格 | 数量 |
| abs811046-5mg | 现货 | ￥789.00 | - + |
| abs811046-10mg | 现货 | ￥1323.00 | - + |
| abs811046-50mg | 现货 | ￥2668.00 | - + |
| abs811046-100mg | 现货 | ￥3628.00 | - + |
大包装询价| 产品描述 | ||
| 描述 | Entecavir is a nucleoside analog (more specifically, a guanosine analogue) that inhibits reverse transcription, DNA replication and transcription in the viral replication process. Entecavir is an oral antiviral drug used in the treatment of hepatitis B infection. | |
| 纯度 | >98% | |
| 储存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. | |
| 基本信息 | ||
| 别名 | ETV; Baraclude; SQ 34676; BMS 200475; SQ34676; BMS200475; SQ-34676; BMS-200475 | |
| 可溶性/溶解性 | DMSO Solubility: 59 mg/mL (199.8 mM) | |
| 生物活性 | ||
| 靶点 | Reverse Transcriptase | |
| In vitro(体外研究) | Entecavir-triphosphate is a highly potent inhibitor of wild-type HBV Pol and is 100- to 300-fold more potent than lamivudine-triphosphate against 3TC-resistant HBV Pol. Entecavir inhibits the replication of 3TC-resistant HBV, but 20- to 30-fold higher concentrations are required. Entecavir results in an impressive reduction of serum viral DNA with covalently closed circular DNA and hepatitis B viral core antigen negativity in liver biopsy specimens. Entecavir has potent activity (EC50, 0.1 nM) against HIV in a unique single-cycle, single-cell-based pseudovirus assay (24) with CD4+ lymphocytes using a green fluorescent protein reporter fluorescence-activated cell sorter assay as the endpoint. | |
| In vivo(体内研究) | Entecavir causes a 4-log drop in serum DHBV DNA levels within 80 days and a slower 2- to 3-log drop in serum DHBV surface antigen (DHBsAg) levels within 120 days in ducks. Entecavir treatment reduces DHBV DNA replicative intermediates 70-fold in the liver, while the level of the stable, template form, covalently closed circular DNA decreases only 4-fold in ducks. Entecavir treatment reduces both the intensity of antigen staining and the percentage of antigen-positive hepatocytes in the liver, but the intensity of antigen staining in bile duct cells appeares not to be effected in ducks. | |
| 温馨提示：本产品仅作科研实验使用，不支持临床等研究 |
- 实验方法 实验条件
共 0张，还能上传 8张 提交
- 提示： 尊敬的客户您好，如果您对我们的产品有什么疑问或想要了解的，可以点击“我要提问”按钮填写您的疑问。
提交不成功？请联系info@absin.cn。
Certificate of Analysis(COA)
